B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Cassava Sciences (SAVA – Research Report) today and set a price target of $72.00. The company's shares closed last Wednesday at $40.62, close to its 52-week low of $31.44. According to TipRanks.com, Mamtani is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -22.7% and a 26.0% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Madrigal Pharmaceuticals, and Cognition Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cassava Sciences with a $121.50 average price target, which is a 198.
https://www.tipranks.com/news/blurbs/b-riley-financial-keeps-their-buy-rating-on-cassava-sciences-sava?utm_source=advfn.com&utm_medium=referral
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Cassava Sciences Charts.
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Cassava Sciences Charts.